12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Trobalt retigabine regulatory update

Germany's Federal Joint Committee (G-BA) said adjunctive epilepsy drug Trobalt retigabine from GlaxoSmithKline provides no additional benefit over comparators. The decision is in line with a February assessment from the German Institute for Quality and Efficiency in Health Care (IQWiG), which said GSK's submission contained no evaluable data...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >